Connect with us


University adopts AI-powered cancer diagnostics solution  

Avatar photo



Artificial intelligence is used at the University of Pittsburgh Medical Centre to support pathologists in diagnosing prostate cancer

A leader in AI-powered cancer diagnostics Ibex Medical Analytics has just announced the live deployment by the University of Pittsburgh Medical Center (UPMC) of Galen Prostate, an AI-based solution that supports pathologists during cancer diagnosis. 

 The Galen suite of solutions is used in routine clinical practice at laboratories, hospitals and health systems worldwide. 

Digitised prostate biopsies

Prostate biopsies at UPMC are now digitised and analysed by Galen Prostate’s AI algorithm ahead of pathologists’ review, providing them with multiple diagnostic insights and decision support tools that can help improve the quality of cancer diagnosis and reduce turnaround time.

“Investing heavily”

 Joseph Mossel, Co-Founder and Chief Executive Officer at Ibex Medical Analytics said, “We are investing heavily to bring our AI-powered digital pathology solutions to the U.S. market and are proud to see UPMC’s ongoing leadership. 

Pathology serves as a cornerstone to medical care, requiring the provision of accurate and timely diagnosis for every patient to better guide treatment decisions and improve survival rates. A

s cancer incidences continue to rise at alarming rates, with prostate cancer occurring in 12 percent of men alone, we are eager to bring Galen Prostate to additional healthcare systems and laboratories, supporting pathologists with automated decision-support tools.”  

UPMC previously published their pioneering work with Galen Prostate in The Lancet Digital Health,  demonstrating very high accuracy rates for Galen in prostate cancer detection as well as in the detection and assessment of other clinically relevant features such as Gleason grading, peri-neural invasion and tumour sizing.  

Prostate algorithm

The prostate algorithm was trained on enriched data sets that included rare prostatic malignancies and can calculate a Gleason score, tumour size and percentage for each cancer slide, which may help pathologists save review time and reduce subjectivity.    

Rajiv Dhir, MD, MBA, Medical Director of Anatomic Pathology Services at UPMC said: “Galen Prostate serves as a “digital assistant” for our pathologists, helping automate routine processes and providing augmented insights for each biopsy,”

“We look forward to expanding the deployment of this technology across our network as we adopt digital workflows that enable our pathology departments to increase efficiency, optimise workflow and ensure the highest standard of care and long-term outcomes for cancer patients.”

The suite of solutions is the most widely deployed AI technology in pathology, supporting pathologists worldwide with augmented diagnostic capabilities during diagnosis of breast, prostate, and gastric biopsies.

Improving the diagnostic accuracy, reducing turnaround time, boosting productivity and improving user experience for pathologists, Galen has demonstrated excellent outcomes across multiple clinical studies performed in different pathology labs and diagnostic workflows.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories